Critical Review: Zealand Pharma A/S (OTCMKTS:ZLDPF) & Creative Medical Technology (NASDAQ:CELZ)

Creative Medical Technology (NASDAQ:CELZ) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

1.4% of Creative Medical Technology shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Creative Medical Technology and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Zealand Pharma A/S	58.86%	18.53%	17.14%

Analyst Ratings

This is a breakdown of current ratings and target prices for Creative Medical Technology and Zealand Pharma A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1	0	1	0	2.00
Zealand Pharma A/S	1	7	1	1	2.20

Volatility & Risk

Creative Medical Technology has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.

Valuation & Earnings

This table compares Creative Medical Technology and Zealand Pharma A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10,000.00	784.21	-$5.99 million	($2.07)	-0.57
Zealand Pharma A/S	$1.40 billion	2.66	$977.29 million	$6.03	8.59

Zealand Pharma A/S has higher revenue and earnings than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Zealand Pharma A/S beats Creative Medical Technology on 9 of the 13 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.